We won't rest until every deadly breast cancer is detected early
- for better outcomes for everyone, everywhere.
In the world's most developed countries, approximately 1 in 8 women will be diagnosed with invasive breast cancer. And when detected early, their chances of survival improve drastically.
And what about all the women in all the other countries in the world?
This is where our story begins.
Because the truth is this: screening isn’t available to most women — and when it is, far too many deadly breast cancers are either missed or caught too late.
We can do better. And we are doing better.
We create safe, reassuring opportunities for reliable breast cancer screening, and we're making them accessible to everyone. Combining proven, state-of-the-art technology with the experience and expertise of leading physicians, we deliver measurable impact, backed by clinical evidence.
Because behind every case of breast cancer is a person. Someone’s mother, daughter, sister, partner, friend. One of us.
And even one undetected, deadly breast cancer is one too many.
Spin-off from Merantix Venture Studio
First screening centers in Germany joined our journey as development partners
Vara certified as a CE (class IIb) medical device
€6.5M Series A led by OMERS Ventures, Toronto
Our journey began as part of Merantix, Europe’s leading venture studio for Artificial Intelligence. In November 2018, we ventured out on our own. That said, we will always be a part of the Merantix family, and will always call the AI Campus our home — ensuring we’re always at the forefront of machine learning technology.